NTRK1 and cancer: Hence, targeting tyrosine kinase receptors, for example by the anti-EGFR antibodies nimotuzumab and cetuximab, and the EGFR inhibitors afatinib, erlotinib, and gefitinib, results in enhanced expression of MHC-I and APM components in different cancer cell lines as well as in cancer patients [185,198,199,200,201,202].